Article

(2019) Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial. Bmc Complementary and Alternative Medicine. p. 11. ISSN 1472-6882

(2019) Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with nonalcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. Nutrition & Metabolism. p. 13. ISSN 1743-7075

(2018) Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial. Nutrition & Metabolism. p. 12. ISSN 1743-7075

(2018) The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial. Nanomedicine Journal. pp. 67-76. ISSN 2322-3049

(2017) Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol. Bmj Open. p. 7. ISSN 2044-6055

(2017) The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial. Trials. p. 9.